More Biosimilars Marketed in Germany, Switzerland Than U.S. – Consumer Health News & More Trending News

FRIDAY, Dec. 2, 2022 (HealthDay News) — More biosimilars have been marketed in Germany and Switzerland than in the United States, however uptake has elevated over time in all nations, in line with a research revealed on-line Dec. 2 in JAMA Network Open.

David L. Carl, from the University of Zurich, and colleagues examined uptake and costs of biosimilars in the United States versus Germany and Switzerland in a cohort research. For 2011 to 2020, costs and gross sales information had been extracted from public and industrial databases.

The research cohort included 15 biosimilars and 6 biologics for the United States; 52 and 15 for Germany; and 28 and 13 for Switzerland. The researchers discovered that in all nations, uptake of biosimilars elevated over time. On common, the very best biosimilar market share at launch was seen in Germany; nonetheless, in the United States, it elevated on the quickest price. Monthly therapy prices of biosimilars had been a median of 1.94 and a couple of.74 greater in the United States versus the corresponding prices in Germany and Switzerland.

“Policies for drug pricing negotiations in the United States against anticompetitive practices of exclusionary contracts could allow biosimilars to enter the market sooner and at lower costs, which could result in lower health care costs and improved patient access,” the authors write. “Awareness of biosimilars should be promoted to increase the uptake of biosimilars in all three countries.”